• RFID-Enabled Dispensing and Intelligent Inventory Management Software Aim to Unlock Greater Inventory Accuracy and Streamline Medication Management in Operating Rooms and Outpatient Clinics

FORT WORTH, Texas / May 14, 2025 / Business Wire / Omnicell, Inc. (Nasdaq:OMCL) (“Omnicell” or the “Company”), a leader in transforming the pharmacy and nursing care delivery model, today announced new products designed to streamline workflows and enhance inventory visibility and management in perioperative and clinic settings. These products, which leverage RFID tracking and intelligent software workflows, expand Omnicell’s connected platform that is intended to automate medication management processes and deliver intelligent insights to drive clinical and operational outcomes across all settings of care.

“As healthcare facilities face ongoing staffing shortages and enterprise expansion, we believe resulting disconnected systems and processes introduce opportunities for error and risk,” said Nish Parekh, senior vice president and chief product officer at Omnicell. “Omnicell is focused on delivering scalable solutions that are designed to grow visibility, enhance intelligence, and streamline workflows, ultimately helping to close gaps in medication management across the care continuum.”

MedTrack RFID Line

We believe the path to the industry-defined vision of the Autonomous Pharmacy demands full visibility to medication use throughout the health system. RFID tracking of medications is expected to provide enhanced visibility of tagged medications. When incorporated into existing pharmacy automation, it should drive more efficient workflows, and is anticipated to help reduce medication errors, stockouts, waste, and cost.

Omnicell has announced the launch of a new line of RFID products, MedTrack, that are intended to increase accuracy and visibility of medications, make user workflows more efficient, and free time for clinicians to focus on higher value work.

The initial offering is MedTrack – OR, an RFID-enabled, single-deep drawer that is built to support operating room and anesthesia workflows and is designed to automatically track non-controlled medications without disrupting provider workflows. This is intended to help enable providers to focus on patient care versus documentation and to enable a ‘grab-and-go’ medication dispensing workflow. In the event of surgical emergencies, MedTrack OR is designed to provide instant access to essential medications while automatically updating Anesthesia WorkStation inventory counts once the user logs out. Automating this layer of medication tracking is expected to help clinical teams enhance provider satisfaction and patient safety and help ensure inventory accuracy and reduce stockouts.

MedVision

Outpatient clinics are often areas where health systems lack insight and control of medication inventory. Many of these settings are driven by manual processes such as hand-written tabulation and fax/email ordering has the potential to introduce inconsistencies and may lead to stockouts and higher drug costs.

MedVision is a web-enabled software product designed to deliver workflows and inventory management tools to help enable a health system’s outpatient clinics to restock medications directly from central pharmacies or Centralized Services Centers (CSCs). The solution is intended to provide real-time clinic medication inventory data that is accessible through intuitive dashboards. It is engineered to trigger automatic reordering from the central pharmacy or CSC when established par levels get low. The software also offers mobile device support for on-the-go inventory management in clinic storerooms and an optional integration with Epic medication administration record (MAR) that is built to automatically update inventory when a medication is administered from the electronic health record.

“MedVision helps us optimize medication procurement for our clinics,” says Brandon McLain, Associate Vice President of Pharmacy Operations at Baptist Health. “The software allows our clinics to order medications in individual unit doses, something we were unable to do through our wholesalers, which helps us reduce costs and waste. The automatic reordering functionality also ensures our clinic nurses and medical assistants don’t have to worry about the drug procurement side of the business, keeping them focused on patient care.”

Omnicell Innovation Lab

Earlier today, Omnicell announced the opening of the Company’s new Innovation Lab in Austin, Texas, a hub dedicated to addressing challenges across the medication and supply management journey. The Innovation Lab aims to be uniquely focused on defining and delivering opportunities that are intended to make healthcare operations more efficient and drive improved clinical and operational outcomes. We believe the opening of this new facility underscores Omnicell’s ongoing commitment to delivering innovation that is outcome-driven and designed to ease the burden on frontline staff in support of safer, smarter care.

To learn more about Omnicell’s outcomes-centric solutions, visit omnicell.com.

About Omnicell

Since 1992, Omnicell has been committed to transforming pharmacy and nursing care through outcomes-centric solutions designed to deliver clinical and business outcomes across all settings of care. Through a comprehensive portfolio of robotics and smart devices, intelligent software workflows, and data and analytics, all optimized by expert services, Omnicell solutions are helping healthcare facilities worldwide to uncover cost savings, improve labor efficiency, establish new revenue streams, enhance supply chain control, support compliance, and move closer to the industry-defined vision of the Autonomous Pharmacy. To learn more, visit omnicell.com.

From time to time, Omnicell may use the Company’s investor relations website and other online social media channels, including its Twitter handle www.twitter.com/omnicell, LinkedIn page www.linkedin.com/company/omnicell, and Facebook page www.facebook.com/omnicellinc, to disclose material non-public information and comply with its disclosure obligations under Regulation Fair Disclosure (“Reg FD”).

OMNICELL and the Omnicell logo are registered trademarks of Omnicell, Inc. or one of its subsidiaries.

Forward-Looking Statements

To the extent any statements contained in this press release deal with information that is not historical, these statements are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, statements including the words “expect,” “intend,” “may,” “will,” “should,” “would,” “could,” “plan,” “potential,” “anticipate,” “believe,” “forecast,” “guidance,” “outlook,” “goals,” “target,” “estimate,” “seek,” “predict,” “project,” and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to the occurrence of many events outside Omnicell’s control. Such statements include, but are not limited to, Omnicell’s expectations regarding our planned new products, solutions, services, technologies and innovations and developing new or enhancing existing products, solutions, services, technologies and innovations, including our MedTrack RFID Line, MedTrack – OR, MedVision or the Innovation Lab, and the related objectives and expected benefits (and any implied financial impact), maximizing technology in an effort to enhance clinical and operational outcomes and statements about Omnicell’s strategy, plans, objectives, promise and purpose, goals, opportunities, and growing the Company’s portfolio. Actual results and other events may differ significantly from those contemplated by forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties. These risks and uncertainties include, among other things, (i) unfavorable general economic and market conditions, including the impact and duration of inflationary pressures, (ii) Omnicell’s ability to take advantage of growth opportunities and develop and commercialize new solutions and enhance existing solutions, (iii) reduction in demand in the capital equipment market or reduction in the demand for or adoption of our solutions, systems, or services, (iv) risks related to Omnicell’s investments in new business strategies or initiatives, including its transition to selling more products and services on a subscription basis, (v) risks related to failing to maintain expected service levels when providing our SaaS and Expert Services or retaining our SaaS and Expert Services customers, (vi) Omnicell’s ability to meet the demands of, or maintain relationships with, its institutional, retail, and specialty pharmacy customers, (vii) risks related to the incorporation of artificial intelligence technologies into our products, services and processes or our vendors offerings, (viii) continued and increased competition from current and future competitors in the medication management automation solutions market and the medication adherence solutions market, (ix) risks presented by government regulations, legislative changes, fraud and anti-kickback statues, products liability claims, the outcome of legal proceedings, and other legal obligations related to healthcare, privacy, data protection, and information security, and the costs of compliance with, and potential liability associated with, our actual or perceived failure to comply with such obligations, including any potential governmental investigations and enforcement actions, litigation, fines and penalties, exposure to indemnification obligations or other liabilities, and adverse publicity related to the same, (x) any disruption in Omnicell’s information technology systems and breaches of data security or cyber-attacks on its systems or solutions, including the previously disclosed ransomware incident and any potential adverse legal, reputational, and financial effects that may result from it and/or additional cybersecurity incidents, as well as the effectiveness of business continuity plans during any future cybersecurity incidents, (xi) Omnicell’s ability to recruit and retain skilled and motivated personnel, (xii) Omnicell’s ability to protect its intellectual property, (xiii) risks related to the availability and sources of raw materials and components or price fluctuations, shortages, or interruptions of supply, (xiv) Omnicell’s dependence on a limited number of suppliers for certain components, equipment, and raw materials, as well as technologies provided by third-party vendors, and (xv) other risks and uncertainties further described in the “Risk Factors” section of Omnicell’s most recent Annual Report on Form 10-K, as well as in Omnicell’s other reports filed with or furnished to the United States Securities and Exchange Commission (“SEC”), available at www.sec.gov. Forward-looking statements should be considered in light of these risks and uncertainties. Investors and others are cautioned not to place undue reliance on forward-looking statements. All forward-looking statements contained in this press release speak only as of the date of this press release. Omnicell assumes no obligation to update any such statements publicly, or to update the reasons actual results could differ materially from those expressed or implied in any forward-looking statements, whether as a result of changed circumstances, new information, future events, or otherwise, except as required by law.